Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Dow
Mallinckrodt
Chinese Patent Office
Teva
Chubb
Colorcon
Medtronic
Boehringer Ingelheim
Harvard Business School

Generated: October 17, 2017

DrugPatentWatch Database Preview

Ge Healthcare Company Profile

« Back to Dashboard

What is the competitive landscape for GE HEALTHCARE, and when can generic versions of GE HEALTHCARE drugs launch?

GE HEALTHCARE has fifty-five approved drugs.

There are six US patents protecting GE HEALTHCARE drugs.

There are one hundred and five patent family members on GE HEALTHCARE drugs in thirty countries and sixty-seven supplementary protection certificates in fourteen countries.

Summary for Applicant: Ge Healthcare

International Patents:105
US Patents:6
Tradenames:61
Ingredients:43
NDAs:55
Drug Master File Entries: (click here to view)5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
SELENOMETHIONINE SE 75
selenomethionine se-75
INJECTABLE;INJECTION017257-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
XENON XE 133
xenon xe-133
GAS;INHALATION017687-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
OMNIPAQUE 300
iohexol
SOLUTION;INJECTION, ORAL, RECTAL020608-002Oct 24, 1995RXNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
HYPAQUE
diatrizoate meglumine
INJECTABLE;INJECTION016403-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
INDICLOR
indium in-111 chloride
INJECTABLE;INJECTION019862-001Dec 29, 1992RXYesYes► Subscribe► Subscribe► Subscribe
Ge Healthcare
SODIUM IODIDE I 123
sodium iodide i-123
CAPSULE;ORAL017630-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
ISOPAQUE 440
calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium
INJECTABLE;INJECTION016847-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
INDIUM IN 111 OXYQUINOLINE
indium in-111 oxyquinoline
INJECTABLE;INJECTION019044-001Dec 24, 1985RXYesYes► Subscribe► Subscribe► Subscribe
Ge Healthcare
NEPHROFLOW
iodohippurate sodium i-123
INJECTABLE;INJECTION018289-001Dec 28, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
SODIUM PERTECHNETATE TC 99M
technetium tc-99m sodium pertechnetate
SOLUTION;INJECTION, ORAL017471-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 1997► Subscribe► Subscribe
Ge Healthcare
VISIPAQUE 320
iodixanol
INJECTABLE;INJECTION020351-002Mar 22, 1996► Subscribe► Subscribe
Ge Healthcare
AMIPAQUE
metrizamide
INJECTABLE;INJECTION017982-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ge Healthcare
VISIPAQUE 270
iodixanol
INJECTABLE;INJECTION020808-001Aug 29, 1997► Subscribe► Subscribe
Ge Healthcare
TESLASCAN
mangafodipir trisodium
INJECTABLE;INJECTION020652-001Nov 26, 1997► Subscribe► Subscribe
Ge Healthcare
MPI DMSA KIDNEY REAGENT
technetium tc-99m succimer kit
INJECTABLE;INJECTION017944-001May 18, 1982► Subscribe► Subscribe
Ge Healthcare
CERETEC
technetium tc-99m exametazime kit
INJECTABLE;INJECTION019829-001Dec 30, 1988► Subscribe► Subscribe
Ge Healthcare
OMNISCAN
gadodiamide
INJECTABLE;INJECTION020123-001Jan 8, 1993► Subscribe► Subscribe
Ge Healthcare
ISOPAQUE 440
calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium
INJECTABLE;INJECTION016847-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ge Healthcare
ISOPAQUE 280
calcium; meglumine; metrizoic acid
INJECTABLE;INJECTION017506-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ge Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,558,854 Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas► Subscribe
9,134,328Methods of using benzothiazole derivative compounds and compositions► Subscribe
8,404,213Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
5,393,524 Methods for selecting and using gases as ultrasound contrast media► Subscribe
5,666,526 Method and system for supporting scrollable, updatable database queries► Subscribe
8,911,707Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
6,156,292 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
5,558,094 Methods for using persistent gases as ultrasound contrast media► Subscribe
7,854,920Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
5,573,751 Persistent gaseous bubbles as ultrasound contrast media► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ge Healthcare Drugs

Country Document Number Estimated Expiration
Japan2012102106► Subscribe
World Intellectual Property Organization (WIPO)2009027452► Subscribe
Australia2011200667► Subscribe
China1264600► Subscribe
Australia3995997► Subscribe
BrazilPI0408274► Subscribe
Norway313577► Subscribe
Spain2536449► Subscribe
China1285582► Subscribe
China1535268► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ge Healthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015Austria► SubscribePRODUCT NAME: (18F) - FLUTEMETAMOL; REGISTRATION NO/DATE: EU/1/14/941 (MITTEILUNG) 20140826
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
41/2009Austria► SubscribePRODUCT NAME: PACLITAXEL ALBUMIN
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
3 5003-2015Slovakia► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2015001Lithuania► SubscribePRODUCT NAME: FLUTEMETAMOLUM (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C0050France► SubscribePRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/428/001 DU 20080111; REGISTRATION NO/DATE AT EEC: EU/1/07/428/001 DU 20080111
2014000065Germany► SubscribePRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Healthtrust
McKinsey
Cipla
Boehringer Ingelheim
Federal Trade Commission
AstraZeneca
Queensland Health
Citi
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot